Home

David Hollander

CIK 1793796 · Chief R&D Officer · last filed 2026-09-03

David Hollander is a Chief R&D Officer who has filed 14 SEC Form 4 insider transactions across 4 companies since 2019. The most recent filing, for MANE, was dated Sep 3, 2026. Across all open-market trades the lifetime net is −$16.3K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $955.1K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$955.1K

Companies

4

Total Filings

14

Lifetime Open-Market Net

-$16.3K

Filer Profile

Reported Address
C/O AERIE PHARMACEUTICALS, INC.
4301 EMPEROR BLVD., SUITE 400
DURHAM, NC 27703
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
MANE Chief R&D Officer 9,650 $98.97 $955.1K $0 1 2026-09-03
KPRX Director — $2.65 — $0 6 2026-06-12
Revance Therapeutics, Inc. (RVNC) Delisted CMO & Global Therapeutics Lead 0 $3.65 $0 -$16.3K 2 2025-02-06
AERIE PHARMACEUTICALS INC (AERI) Delisted Chief R&D Officer 30,749 $15.25 $468.9K $0 5 2022-02-08

Recent Filings

14 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-03 MANE Grant (A) +9,650 $0 EDGAR
2026-06-12 KPRX Grant (A) — $0 EDGAR
2025-04-02 KPRX Grant (A) — $0 EDGAR
2025-02-06 Revance Therapeutics, Inc. (RVNC) Delisted Mixed −104,945 -$35.5K EDGAR
2024-11-19 Revance Therapeutics, Inc. (RVNC) Delisted Sell (S) −3,908 -$16.3K EDGAR
2024-07-03 KPRX Grant (A) — $0 EDGAR
2023-10-03 KPRX Grant (A) — $0 EDGAR
2023-03-07 KPRX Grant (A) — $0 EDGAR
2022-02-08 AERIE PHARMACEUTICALS INC (AERI) Delisted Tax (F) −927 -$6.5K EDGAR
2022-02-03 KPRX Grant (A) — $0 EDGAR
Showing 1–10 of 14
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.